ImageBiopsy Lab, an Austria-based company, and Radiobotics, a Danish firm, have formed a strategic partnership to introduce artificial intelligence (AI) assisted disease diagnostics in the Germany, Austria, and Switzerland (DACH) region. The utilization of AI in disease diagnostics has gained significant traction in recent years, with the AI market projected to reach $93 billion this year, according to a report by GlobalData. This partnership aims to provide AI-assisted technology for diagnosing musculoskeletal, orthopedic, and trauma-related conditions. By automating the interpretation of X-rays and MRI images, this technology is set to enhance diagnostic efficiency. It will analyze medical images, conduct measurements, and generate scores to facilitate interpretation while reducing the manual workload. Moreover, it is anticipated to improve fracture detection workflows.
Dr. Richard Ljuhar, CEO of ImageBiopsy Lab, emphasized the importance of understanding physicians’ diagnostic workflows and needs before implementing AI. The collaboration between ImageBiopsy Lab and Radiobotics is the result of extensive consultation with leading musculoskeletal radiologists, orthopedic specialists, and traumatologists. ImageBiopsy Lab’s existing FDA-approved radiological image processing software, IB Lab LAMA, has already made significant strides in limb and angle measurements on leg X-rays, supporting orthopedic surgeons in patient management. ImageBiopsy Lab also offers IB Lab KOALA, which can detect signs of knee osteoarthritis using joint measurements, and IB Lab SQUIRREL module for scoliosis assessment. Radiobotics, on the other hand, brings to the table its fracture detection AI software, RBfracture, which efficiently identifies possible fracture locations in X-ray images, reducing analysis time, especially in trauma settings. This partnership aims to leverage AI to enhance disease diagnostics in the DACH region and improve patient care.
